You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Boston Scientific receives FDA clearance for Asurys fluid management system

Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences

Rocket Pharmaceuticals secures FDA approval for Kresladi gene therapy in severe LAD-I

Pharming receives positive CHMP opinion for Joenja marketing authorisation

Biocytogen partner NEOK Bio secures FDA IND clearance for cancer therapy candidate

Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator

Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA

Lupin reports tentative FDA approval for Pitolisant Tablets

Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics

Merck to acquire Terns Pharmaceuticals for USD6.7bn

Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency

Hope Medicine reports first patient dosed in Phase III trial of HMI-115

Orsini chosen as single-source specialty pharmacy partner for Glaukos' Epioxa

GE HealthCare's Photonova Spectra gains FDA clearance

Futura Medical reports positive home user test results for Eroxon and Intense variant

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026